
Galapagos
has developed a target discovery platform that provides novel
starting points for drug and antibody therapies, thereby addressing
the industry's need for innovative, disease-modifying medicines.
Galapagos is exploiting this platform in disease areas for which
there is a clear need for better medicines. The Company's product
portfolio consists mainly of new mode-of-action drugs in bone
and joint diseases as well as programs in cancer metastasis,
cachexia and orphan diseases. To enable the progression of a
broad portfolio of programs, Galapagos has established risk
sharing alliances with big pharma companies in specific disease
areas. Through an alliance with MorphoSys, Galapagos is also
developing new antibody therapies in bone and joint diseases.
Galapagos' service division, which includes BioFocus and the
recently acquired service operations from Argenta, offers a
full suite of target-to-drug discovery products and services
to pharma, biotech and patient foundations - encompassing target
and drug discovery through to the delivery of pre-clinical candidates.

March
5,
2010
Galapagos
reports record revenues and net profit for 2009, foresees sustained
profitability
View
webcast presentation
Read more
February
23, 2010
Galapagos
successfully completes Phase I clinical trials for rheumatoid
arthritis candidate drug GLPG0259
Read more
February
22, 2010
Galapagos
delivers third candidate drug in GSK alliance, receives €5.7
million
Read more